Q1 2026 headline results and setup

Corteva (CTVA) opened 2026 with Q1 revenue of US$4.9 billion and basic EPS of US$1.07, with trailing twelve month net income of US$1.25 billion giving investors a fuller view of the current earnings run rate. The company reported quarterly revenue of US$4.42 billion in Q1 2025 and US$4.91 billion in Q1 2026, while basic EPS moved from US$0.97 to US$1.07 over the same period as trailing net profit margins held close to 7%. With earnings growth forecasts sitting above revenue expectations, the latest print highlights how efficiently Corteva is converting sales into profit.

See our full analysis for Corteva.

With the headline numbers established, the next step is to see how this earnings profile lines up against the dominant narratives around Corteva's growth potential, risk profile, and margin trajectory.

Margins steady around 7% net income

• Over the last 12 months, Corteva generated net income of US$1.25b on US$17.9b of revenue, which works out to a 7.0% net profit margin compared with 6.8% a year earlier.
• Analysts' consensus view links this steady margin profile to higher quality products and cost discipline, and the current numbers partly back that up while also setting some limits:
  • Consensus points to demand for resilient seeds and biological products as a driver of better pricing, and the 7.0% margin on US$17.9b in sales is consistent with that higher value mix.
  • At the same time, revenue forecasts of about 2.7% growth per year keep expectations in check, so the small step up in margin from 6.8% to 7.0% matters more for earnings than for top line expansion.

TTM earnings up 9.6% with one large loss

• Trailing 12 month earnings grew 9.6% year over year to US$1.25b, but that figure is affected by a single non recurring loss of US$778.0m in the period.
• Consensus narrative leans on cost optimization and productivity gains to support earnings growth, and the data both supports that idea and highlights where risks show up:
  • Investors looking at the 9.6% earnings growth against relatively modest revenue expansion are likely to see evidence of operating leverage in the cost base, in line with the focus on productivity.
  • Critics highlight that a US$778.0m one off loss distorts the trailing picture, so any view that margins are fully settled needs to acknowledge that earnings volatility is still visible in recent history.

High 43.8x P/E but DCF fair value higher

• Corteva is trading on a P/E of 43.8x versus peer and US Chemicals industry averages of 19.1x and 29.5x, while the current US$81.77 share price sits below a DCF fair value of US$104.38 and below an analyst price target of US$87.24.
• Consensus commentary that the stock can support premium pricing because of its product mix meets a mixed valuation picture that investors should weigh carefully:
  • Supporters point to forecast earnings growth of about 17.4% per year and a 21.7% gap between the US$81.77 share price and the DCF fair value of US$104.38 as justification for paying more than the sector average P/E.
  • Skeptics instead focus on the 43.8x P/E multiple relative to the 19.1x peer and 29.5x industry levels, arguing that even with earnings growth and a US$87.24 analyst target, the valuation already prices in a lot of that expected progress.

Bulls and skeptics are drawing very different conclusions from the same set of growth, margin, and valuation numbers, so if you want to see how each side connects these figures into a full story, check out the See what the community is saying about Corteva

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Corteva on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, it is because the numbers support more than one story. Move quickly, check the key figures yourself, and weigh both sides using the 3 key rewards and 1 important warning sign

See What Else Is Out There

Corteva's rich 43.8x P/E multiple, modest revenue expectations, and recent non recurring loss mean a lot of optimism is already reflected in the current stock price.

If that combination feels a bit tight for comfort, compare it with companies that pair more grounded pricing with stronger upside using the 44 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.